Arch Biopartners Inc.
ACHFF
$0.39
$0.000.70%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 100.00% | -- | -- | -61.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 100.00% | -- | -- | -61.57% |
| Cost of Revenue | 393.42% | -135.12% | -76.02% | -95.56% | -41.51% |
| Gross Profit | -3,316.07% | 118.24% | 109.05% | 78.28% | -88.14% |
| SG&A Expenses | 257.70% | 18.44% | -15.10% | -19.62% | -67.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 295.06% | -73.30% | -53.30% | -85.05% | -63.34% |
| Operating Income | -478.84% | 82.80% | 74.05% | 52.46% | 64.12% |
| Income Before Tax | -276.09% | 75.80% | 72.90% | 48.94% | 48.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -276.09% | 75.80% | 72.90% | 48.94% | 48.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -276.09% | 75.80% | 72.90% | 48.94% | 48.34% |
| EBIT | -478.84% | 82.80% | 74.05% | 52.46% | 64.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -267.39% | 77.44% | 74.76% | 51.47% | 50.00% |
| Normalized Basic EPS | -265.52% | 77.11% | 73.44% | 50.59% | 50.00% |
| EPS Diluted | -267.39% | 77.44% | 74.76% | 51.47% | 50.00% |
| Normalized Diluted EPS | -265.52% | 77.11% | 73.44% | 50.59% | 50.00% |
| Average Basic Shares Outstanding | 1.79% | 7.79% | 5.34% | 4.32% | 3.96% |
| Average Diluted Shares Outstanding | 1.79% | 7.79% | 5.34% | 4.32% | 3.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |